TVM Capital Life Science invests in AurKa Pharma
TVM Capital Life Science has made an undisclosed investment in AurKa Pharma Inc, a Montréal-based company created to develop to proof-of-concept a compound originally discovered by Eli Lilly and Co. The compound has the potential to treat certain types of solid tumors, including small cell lung cancer and treatment-resistant breast cancer. Led by CEO Caroline Fortier, AurKa plans to begin clinical development next year. TVM Capital Life Science, which has an office in Montréal, invested via TVM Life Science Ventures VII, which raised US$201.6 million in late 2014. Eli Lilly was one of the fund's backers.
19 September 2016•5 mins read
